Agoracom Blog

INTERVIEW: Avalon Rare Metals Inaugural Q&A – May 21, 2015

Posted by AGORACOM-JC at 10:38 AM on Thursday, May 21st, 2015

Investment Highlights

  • Avalon offers diversified exposure to a broad range of rare metals and minerals (including tin) that are critical raw materials for clean technology
  • Nechalacho Project, with a completed feasibility study, an approved Environmental Assessment and a rare earth oxide refining solution in place, is uniquely positioned to bring a new supply of the scarce, yet vital heavy rare earths to the market
  • East Kemptville Tin-Indium Project was re-activated in 2014 and is advancing steadily with a new NI 43-101 resource estimate and a conceptual re-development study completed Feb 2015
  • Separation Rapids Lithium Minerals (Petalite) Project is advancing due to new demand from the glass-ceramics industry for the petalite product and for its potential to produce high purity lithium chemicals for the growing rechargeable battery market

Hub On AGORACOM / Corporate Profile / Watch Interview Now!

Bioavailability Testing to Commence on Lexaria’s Patent-Pending Technology

Posted by AGORACOM-JC at 8:42 AM on Wednesday, May 20th, 2015

KELOWNA, BC / May 20, 2015 / Lexaria Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) is pleased to announce it has engaged Absorption Systems LP in the USA, to begin third party in vitro tests using a human intestinal tissue model to evaluate the cannabidiol (CBD) permeability of its patent-pending technology that infuses cannabinoid compounds within lipids.

The study will assess CBD permeability achieved with our proprietary ViPova(TM) tea formulation at multiple sampling time points compared to positive and negative controls under strict experimental conditions. In vitro testing using human tissue models can be preferable to animal testing since human cells can be used directly to provide species-specific permeability results.

“Although we cannot know in advance the outcome of such tests, the results have the potential to materially affect future outcomes for the Company,” said John Docherty, president of Lexaria. “We have a wealth of anecdotal evidence from our growing ViPova(TM) customer base extolling the marked effects of our CBD-infused tea and we look forward to the outcome of this study to help quantify this in detail.”

It is generally accepted in pharmacological sectors that the bioavailability of any active ingredient is one of the most important factors determining its effects on the body. Enhanced bioavailability can be extremely useful and is highly valued for any useful molecule, including CBD and tetrahydrocannabinol (THC).

Lexaria expects to begin this testing in the near future and will report results when they are available in due course, expected within the next 3-4 months.

About Lexaria

Lexaria is a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies. www.lexariaenergy.com

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM)uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

About Absorption Systems

Absorption Systems assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Panama, serves customers throughout the world. For information on the company’s comprehensive contract services and applied research programs, please visit www.absorption.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person, nor that bioavailability testing will produce any positive result. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Lithium Demand Will Grow Faster Than Bulls Imagine

Posted by AGORACOM-JC at 3:20 PM on Tuesday, May 19th, 2015

By Editing NAI
05/13/2015 2:11 a.m.

It all started with Tesla Motors’ (NASDAQ:TSLA) announcement of its battery gigafactory in February 2014. That news was discussed endlessly with breathless excitement. The news sparked a revival in lithium, cobalt and graphite juniors. For example, Western Lithium USA (TSX:WLC), based in Nevada, more than doubled that month. At the time, I wrote a few articles saying that the gigafactory was great news for select graphite companies. I didn’t mention lithium or cobalt, simply because I was less fluent in those. Today, I’m better prepared to articulate the lithium story, one of the hotter sectors in the natural resources space. Why now? I think that the lithium-ion battery might be reaching a “tipping point,” the phrase made famous by Malcolm Gladwell. Please note, I don’t use catchphrases loosely — lithium’s spike in demand is no “black swan” event, and we’re not near “peak lithium,” although we could see supply shortages on the horizon. Tesla’s gigafactory not only caught everyone’s attention, but also caught on so well that there are already five to six announced or in-construction gigafactories (Tesla’s is the largest).

Lithium demand “is spiking” for several reasons, again heavily influenced by the $5-billion Tesla facility. Interestingly, the original concept was that the Tesla facility would be completed by 2020. Now conventional wisdom says 2017 to 2018, another bullish data point. Tesla’s fully electric car was way too awesome for its own good. It guaranteed that new competition would enter the space, and it has. Here’s an abbreviated list of 15 automakers in the plugin-EV (hybrid) or fully EV market: BMW, Mitsubishi, Toyota, Nissan, Honda, Tesla, GM, Ford, Kia, Fiat, Mercedes, Porsche, Volkswagen, Audi and Hyundai. This list probably doesn’t even contain all of the well-known brands. Many of these automakers had no offerings of plugin-EV (hybrid) or fully EVs until after Tesla’s. Here’s another fact, not my opinion: there are dozens of less-well-known brands diving into the race. China and Europe have plenty of them. China is trying mightily to cut down on air pollution and European cities are small enough to be quite amenable to EVs. Check out this article if you don’t believe me! And just wait until ALL hybrids become full EVs. A certainty in my mind.

So many uses, hard to follow demand, harder to forecast

So far I’ve mentioned Tesla’s new paradigm introduction of a “real” EV and the fact that it is attracting MANY competitors. I’ve also pointed to the multiple gigafactories spurred on by Tesla’s. But wait, there’s more. About a week ago, Tesla announced a much-ballyhooed home lithium battery storage system that can run one’s home for up to eight hours. This product is thought to be especially attractive to homes with solar panels. This is yet another shot across the bow warning of another leg up in lithium demand. I guarantee that Elon Musk’s home storage units will attract a lot of competition (some superseded Tesla), and perhaps the need for more battery gigafactories? Tipping point or not, lithium demand is moving substantially higher by the day. By the time analysts come around to forecasting a 12- to 15-percent CAGR from 2015 to 2020, the growth rate could be more like 25 to 35 percent. I have no scientific backing for my projection of 25 to 35 percent, I’m just saying that extrapolating 2012 to 2015 growth factors forward will not work. Don’t make me mention the 200 million electric bikes in China alone, because I will if I have to. Another factoid mentioned far less often is the widespread adoption of hybrid buses, taxis and forklifts (and similar equipment in warehouses around the globe). Is anyone contemplating the replacement lithium batteries that will be required by many electronic devices, power tools and more?

Above, I mentioned Western Lithium, which has a well-deserved market cap of $105 million. Lithium Americas (TSX:LAC) has a $70-million market cap. Before moving down the list, please also consider ASX-listed Orocobre (ASX:ORE), which has a market cap of $425 million and is a pure-play, producing lithium company. Of course, Orcobre is several years ahead of small-cap companies like Dajin Resources (TSXV:DJI) (which trades a combined 365,000 shares per day) and Pure Energy Minerals (TSXV:PE). However, we’ve seen this movie before. When a commodity is in high demand, this is what happens. Small companies acquire or get options on prospective deposits, they stake new ground and they explore and develop as available capital prudently allows.

Time is money. Do new entrants really want to start a greenfields project? Or might they prefer to save two, three, four years’ worth of money and leg work provided by a well-run junior? I believe that in a strong market — or dare I say a bull market — in lithium, companies with the lowest market caps, solid management teams and highly prospective deposits will be sought after. I submit that lithium companies with market caps of $5 to $15 million today have stocks more likely to double, triple, quadruple, quintuple, sextuple, septuple or octuple than some of the abovementioned plays. Sorry, I had to use the word “septuple” at least once in my life.

For example, for Dajin Resources, a return of 10 times on its market cap would still place it at a discounted valuation to Western Lithium. Don’t get me wrong, Dajin has considerably more risk, but also considerably more upside, at least if one shares my bullish view on lithium. Even though Dajin and Pure Energy are behind their peers in reaching initial production, they are actually well ahead of new entrants in terms of permitting, environmental studies, seismic, drilling, community relations, access to infrastructure and mining officials.

Peter Epstein, Founder of epsteinresearch.com

Source: resourceinvestingnews.com

Source: http://www.nai500.com/intelligence/show_article/133053

REMINDER: Deadline for Avalon Q&A Question Submission is End of Business Today

Posted by AGORACOM-JC at 10:25 AM on Tuesday, May 19th, 2015

We are happy to announce the first Avalon Rare Metals Q&A in which investor questions posted to the Avalon HUB will be incorporated into an upcoming interview.

Format of the Q&A is as follows:

1. To post your question, please use the subject line “Q&A”.

2. When you post your question, please check “Question For AGORACOM’ box.

Register Now!

3. Avalon can’t respond to questions related to current, present or future performance of its share price, nor can they provide non-disclosed material information that would violate securities laws.

4. To this end, please try to review questions already posted by fellow shareholders to avoid duplication

5. Please limit your questions to a maximum of 3

6. Deadline for submitting questions is end of business today.

Thank-you and we look forward to your participation in our first Avalon Rare Metals Q&A.

Regards,

AGORACOM

Lexaria Intellectual Property Update

Posted by AGORACOM-JC at 8:24 AM on Friday, May 15th, 2015


KELOWNA, BC / May 15, 2015 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) provides the following update and information regarding its patent-pending technology; how it relates to the delivery of certain active ingredients such as CBD and THC, and how it relates also to market demand.

Lexaria has caused to be filed on April 28, 2015 and May 14, 2015, the latest in a line of provisional patent applications with the United States Patent and Trademark Office regarding its technology that were originally filed beginning in June, 2014. Lexaria’s new patent-pending technology is directed to food and beverage compositions infused with cannabinoids – e.g., THC and/or CBD – that provide enhanced cannabinoid oral bioavailability. We expect the United States Patent and Trademark Office to publish our provisional patent applications roughly in December 2015.

Lexaria’s proprietary process infuses lipids within foods and beverages with cannabinoids and produces compositions with synergistically enhanced cannabinoid absorption and bioavailability. The cannabinoid infused food and beverage compositions have the added benefit of masking the inherent unpleasant taste of cannabinoids to allow for better patient compliance with therapeutically administered cannabinoids.

It is important to understand certain facts:

Smoked or inhaled cannabinoids have reported bioavailabilities ranging from 2-56%, with an average of about 30% (Huestis (2007) Chem. Biodivers. 4:1770-1804; McGilveray (2005) Pain Res. Manag. 10 Suppl. A:15A – 22A). This variability is mainly due to differences in smoking dynamics. Cannabinoids that are absorbed through the mucous membranes in the mouth (buccomucosal application) have bioavailabilities of around 13% (Karschner et al. (2011) Clin. Chem. 57:66-75). By contrast, when cannabinoids are ingested, bioavailability is typically reduced to about 6% (Karschner et al. (2011) Clin. Chem. 57:66-75).

Lexaria’s patent-pending cannabinoid lipid-infusion technology is based in part on the goal of achieving much higher cannabinoid bioavailability than conventional means of oral cannabinoid ingestion.

Oral bioavailability into or approaching the range typical of smoked or inhaled cannabinoids would be potentially disruptive to the entire medical marijuana sector because it would offer patients an efficient option to reduce or even eliminate the need for smoking or inhalation delivery while simultaneously improving conventional edible cannabinoid formats.

To this end, the Company will undertake certain laboratory testing in the coming months to further characterize potentially transformative aspects of the technology and will report the outcome upon completion.

Benefits of the patent-pending technology, include:

1) A positive social health outcome through reduction of smoking of cannabinoids;
2) Improved confidence in consistent delivery of THC or CBD through oral ingestion;
3) Lower cost to consumers relative to conventional edible formats through higher rate of active ingredient delivery;
4) Easy and convenient active ingredient delivery through many readily available common everyday foods;
5) A disruptive competitive advantage for Lexaria versus any company that delivers THC or CBD through any other format, including traditional smoking.

By their nature, new inventions are unpredictable and not always entirely understood in advance. Many complex technologies are being pursued by the broader food and drug industries in relation to more effective delivery of drugs and other ingredients because their traditional oral bioavailability may be poor. Solid lipid nanoparticles, for example, have demonstrated improvements in bioavailability of some Class II, III, and IV drugs as much as 2-25 fold as seen below:

“The US FDA recommended high fat meals for food-effect studies because such fatty meals (800-1000 cal, 50%-65% fat, 25%-30% carbohydrates and 15%-20% proteins) affect GI physiology and maximize drug transfer into the systemic circulation.” (Food and Drug Administration, Guidance for industry: food-effect bioavailability and fed bioequivalence studies, food and drug administration. www.fda.gov)

Maximizing bioavailability is a common aim throughout the food, pharmaceutical and drug industries since efficiencies in delivering active ingredients also deliver many benefits.

About Lexaria

Lexaria is a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies. www.lexariaenergy.com

About ViPova(TM)

ViPova(TM) uses only legal hemp oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that patent-pending applications will result in granted patents, or that competing companies, in their normal course of business, might not introduce other unrelated inventions superior to the Company’s own. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

US DOJ believes Silicon Metal a critical ingredient

Posted by AGORACOM-JC at 11:18 AM on Thursday, May 14th, 2015

Globe Specialty, FerroAtlantica Face Extended Scrutiny on Planned Merger

By William McConnell Follow|05/12/15 – 05:27 PM EDT

NEW YORK The Deal) –Globe Specialty Metals(GSM) faces an extended U.S. Department of Justice review of its $3.1 billion acquisition of rival Grupo FerroÁtlantica. Miami-based Globe disclosed the DOJ’s second request for information in a filing to the Securities and Exchange Commission Monday.

The combination with Madrid-based FerroÁtlantica would create the world’s largest producer of silicon metals, which are critical ingredients for making aluminum, solar panels and other products. FerroÁtlantica is wholly owned by Spain’s Grupo Villar Mir, which will own 57% of the new London-headquartered, Nasdaq-listed company after the merger, with current Globe shareholders holding 43%.

The companies said they continue to expect the transaction to close in the fourth quarter of 2015 despite the DOJ’s decision to extend the investigation beyond the initial 30-day waiting period. Regarding the antitrust investigation, the companies said in their SEC filing that they “continue working cooperatively with the DOJ as it conducts its review of the proposed business combination.”

The companies’ merger agreement contains few antitrust safeguards, indicating little concern for antitrust risk. FerroÁtlantica is not entitled to a reverse breakup fee if the deal is terminated due to failure to obtain regulatory approval. The parties are not obligated to accept divestitures or other conditions sought by regulators if such as move would cause a material adverse effect on their businesses.

Globe Specialty Chairman Alan Kestenbaum side-stepped an analyst’s question about the companies’ possible overlaps during a Feb. 23 conference call to announce the deal. “This has been analyzed and we look forward to working with the regulators and are confident that we’ll be able to get through the process successfully,” was all he would say when asked about potential competition issues raised by the merger during a Feb. 23 conference call.

Globe Specialty maintains that its business is highly competitive. According to the company’s 10-K its primary competitors in the silicon metal and silicon-based alloy markets are Elkem AS, owned by China National Bluestar Group, and FerroAtlantica. There are other significant competitors, though, according to the company, including Rima Industrial and Ligas de Alumino as well as producers in China and the former republics of the Soviet Union. The company also said it faces “continual threats from existing and new competition.”

Nevertheless, Globe Specialty characterized itself as a “highly efficient, low-cost producer” which it attributed in part to manufacturing processes that allow it to capture most of its production by-products for reuse or resale. It also has the capacity to react to changes in market demand by switching production between silicon-based alloy and silicon metal production at low cost.

The company, in its 10-K, did acknowledge that new competitors face difficulty entering the market because of a three- to five-year lead time to obtain the necessary governmental approvals followed by construction time and the need to secure supply sources for raw materials and energy. Those barriers to entry could make the DOJ skeptical that any competition lost by the merger could be replaced by new players in the market.

Source: http://www.thestreet.com/story/13149101/1/globe-specialty-ferroatlantica-face-extended-scrutiny-on-planned-merger.html

CLIENT FEATURE: Xylitol (XYL:TSX-V) Natural Sweetener Co with $8.6M in Revenues for 2014

Posted by AGORACOM-JC at 12:09 PM on Wednesday, May 13th, 2015

Financial Highlights

  • $8,600,000 in revenue for 2014 up from $6,500,000 in 2013

Marquee Customers Include:

Strong Institutional Ownership

  • Dundee Corp 29%
  • SunOpta BioProcess Inc. 26%

What is Xylitol you ask?

  • Xylitol is a sugar alcohol – and no, that doesn’t mean there’s alcohol in it. It’s also known as a polyol. Sugar alcohols contain fewer calories and fewer carbohydrates than other sweeteners. Replacing sugar with xylitol can be helpful if you’re trying to lose weight or even to help prevent weight gain.

What does xylitol taste like?

  • Xylitol is a white crystalline granule that looks and tastes like sugar. The good news is that it doesn’t have the negative side effects associated with sugar. Xylitol is low-calorie, low-carb, diabetic safe and we think it’s guilt free!

Where does your xylitol come from?

  • Xyla brand xylitol is extracted from North American grown hardwood trees, and it’s delicious. We believe the practices employed in the harvesting and processing of our xylitol are ecologically sustainable. Xylitol is also naturally occurring in many fruits and vegetables. Did you know the human body makes about 15 grams of xylitol per day?

Xylitol Canada, Inc. emerged in 2004 as a reseller and distributor of Xylitol and Xylitol products. Based in Toronto, Ontario, the company continued to grow and develop additional brands under the names Sweet Diabetic Delight and Xylitol Canada. Realizing the market potential for high quality, readily available, and consistently priced Xylitol and Xylitol products, the Company broadened its strategic vision in 2009.

Realizing that the void in the Xylitol market was based on inadequate supply and lack of awareness, the company initiated a 2-tier business expansion plan that sought to solve both of these problems. With the vision of a full scale North American Xylitol production facility as a critical element of this strategy, the Company reached out to the Capital markets and formally went public in April of 2010. With the capital base to aggressively address the marketplace, the company immediately began executing its business plan.

Xylitol In The Media

Daytime Toronto – Rogers TV (Aug 2013) – Julie Reid from Xylitol Canada appears with Mari Loewen from Anna Magazine to make some delicious recipes using North American hardwood derived Xyla xylitol.

Daytime Ottawa – Rogers TV (June 2013) - Xylitol Canada’s Julie Reid and naturopath Helene Huot discuss the benefits of Xyla xylitol and share great summer recipes using Xyla.

Is Sugar Toxic? – 60 Minutes (May 4th, 2013) – Sugar is the most addictive substance on earth. It’s also the most dangerous and toxic substance anyone can consume. Sugar has similar affects on the brain like cocaine. Heart disease, cancer, diabetes type II and many more are linked to processed sugar.

Sugary Drinks Linked To 180,000 Deaths Worldwide – CNN (March 19, 2013) – “One in every 100 deaths from obesity-related diseases is caused by drinking sugary beverages,” says study author Gitanjali Singh, a postdoctoral research fellow at the Harvard School of Public Health.

Avalon Rare Metals Announces 1st Online Shareholder Q&A With Don Bubar

Posted by AGORACOM-JC at 11:29 AM on Tuesday, May 12th, 2015

We are happy to announce the first Avalon Rare Metals Q&A in which investor questions posted to the Avalon HUB will be incorporated into an upcoming interview.

Format of the Q&A is as follows:

1. To post your question, please use the subject line “Q&A”.

2. When you post your question, please check “Question For AGORACOM’ box.

Register Now!

3. Avalon can’t respond to questions related to current, present or future performance of its share price, nor can they provide non-disclosed material information that would violate securities laws.

4. To this end, please try to review questions already posted by fellow shareholders to avoid duplication

5. Please limit your questions to a maximum of 3

6. Deadline for submitting questions is Tuesday May 19th (end of business day).

Thank-you and we look forward to your participation in our first Avalon Rare Metals Q&A.

Regards,

AGORACOM

Medical marijuana registry in Quebec called world’s 1st

Posted by AGORACOM-JC at 10:50 AM on Tuesday, May 12th, 2015
The varying levels of THC in medical marijuana could help to shed light on how safe and effective the drug is for different clinical conditions.
The varying levels of THC in medical marijuana could help to shed light on how safe and effective the drug is for different clinical conditions. (Jeff Chiu/Associated Press)

Medical marijuana users in Quebec can now help shed light on the drug’s long-term safety and effectiveness through a new registry at McGill University in Montreal.

McGill said its medical marijuana registry, which launched on Monday, is the first research database of its kind in the world.

The registry meets a requirement of Quebec’s college of physicians, which considers cannabis an experimental therapy. Under provincial regulation, cannabis can only be prescribed as part of a formal study.

Health Canada estimates over 40,000 Canadians legally consume cannabis to relieve symptoms from diseases including multiple sclerosis, HIV, cancer or epilepsy.

While cannabis has been studied for years as a recreational substance, little is known about its medical use, said Dr. Mark Ware, director of clinical research at McGill’s pain management unit.

“I got frankly tired of giving talks and presentations about the potential medical use of cannabis and always having questions for which I did not have answers,” said Ware. “I hope this study is a step in the direction of trying to fill some of these huge knowledge gaps.”

The registry allows doctors and users of medical marijuana to look for any possible safety concerns.

It will also allow researchers to look for clues about what variations of medical marijuana might work best for which conditions.

Combining information on the patients and the drugs could not only identify potential safety considerations but also start to answer questions about the effectiveness of cannabis under certain clinical conditions, Ware added.

Despite expanding access to medical marijuana globally, the university calls the project a world first. Ware said to his knowledge no country or region has set up such a prospective, formally approved clinical project.

The researchers hope to engage doctors on the front lines to participate in the research — an approach that could be adapted to study the safety and effectiveness of other drugs over the long term.

The data collected will not have any identifiable patient information to protect patient privacy.

The registry will remain active for at least 10 years and involve thousands of patients. Ware hopes to share the data with other provinces and potentially other countries.

Source: http://www.cbc.ca/news/health/medical-marijuana-registry-in-quebec-called-world-s-1st-1.3069316

Newnote Financial Acquires 100% Interest in Revenue Generating Online Store Builder PayIvy.com

Posted by AGORACOM-JC at 9:11 AM on Tuesday, May 12th, 2015

Vancouver, British Columbia–(May 12, 2015) – Newnote Financial Corp. (CSE: NEU) (OTCQB: NWWTF) (FSE: 1W4) (the “Company”), is pleased to announce the Company has acquired PayIvy.com, a platform for merchants selling digital products and digital downloads such as e-books, software, graphic designs, web designs and intellectual property. Newnote paid CDN $260,000 in cash and stock.

Key Acquisition Highlights:

  • Revenue Generating
  • Closest competitor Fiverr.com raised $30 million in a Series C round led by Qumra Capital with participation from existing investors Bessemer Venture Partners and Accel Partners in 2014
  • Over 10,000 Merchants strong growing by over 1000 new merchants weekly
  • PayIvy has shown great growth in its first six months, reaching an Alexa ranking of 73,000
  • Processing over $200,000 per month in sales while currently experiencing hyper-growth

PayIvy.com is a multi-vendor website enabling merchants to register and start selling digital products and services online within minutes. Merchants can instantly accept credit cards through PayPal as well as accepting various crypto-currencies including Bitcoin, Litecoin and Omnicoin as payment methods via Coinpayments.

Merchants can sell and publish e-books with more options to protect their digital content from online piracy. A licensing system is available for vendors to sell their software with Hardware ID locking to prevent unauthorized software distribution and sharing. Transactions and sales are recorded on-site with a messaging system for all users. A simple fraud system is added for PayPal payments helping sellers to identify fraudulent users and block them from purchasing. Custom fields are also available for sellers to collect data from customers. Other features include an advanced affiliate program for sellers looking to promote their products.

Newnote is pleased to have PayIvy.com co-founders Lode Kennes from Belgium, Ton Manh Nguyen and David Snyder from Calgary, Alberta to continue with PayIvy daily operations and development. Lode is an advanced web developer specializing in PHP, C#, ASP .NET, Java, Python, HTML, CSS, SQL and Visual Basic. David is the lead interface designer at PayIvy.com and active designer of Coinpayments.net.. Ton will continue to work with developers to maintain and maximize revenue potential on PayIvy.com.

Lode Kennes states: “Although we have experienced great growth in the past six months, PayIvy is yet to show its full potential. With the investment from Newnote, PayIvy will be able to serve more sellers with features that no other site can offer.”

CEO & President of Newnote, Paul Dickson, reports: “This is a very strategic acquisition for Newnote, each of our services will be integrated into one another utilizing our APIs. Merchants can now setup shopwith PayIvy.com, Accept payments through Coinpayments.net, Convert Bitcoin-to-Cash on Cointrader.net and transfer the funds into their bank account or remit overseas instantly. Newnote’s portfolio of Bitcoin centric assets now has a combined total of over 60,000 active users engaged in various crypto-currency activities while processing nearly $2,000,000 per month in Bitcoin transactions. We haven’t fully monetized each of our services during this rapid growth period, plans to do so are imminent.”

PayIvy can be accessed at: http://www.payivy.com

About Newnote Financial Corp.

Newnote Financial Corp. is pioneering innovative crypto-currency and Bitcoin related software products and services geared at the growing business segment of this bourgeoning market. The Company owns and operates the Cointrader.net Bitcoin Exchange, PayIvy.com Online Store Builder, CoinExchange Android App, BitVisits.com Paid-to-Surf Advertising Platform, Bitcoin ATM Machines in London, Tokyo and Vancouver in addition to several other crypto-currency related assets. Newnote has positioned itself to be a leading contender in delivering opportunities to startup businesses world-wide and continues to create new opportunities for its clients and its shareholders. Newnote has a clear vision on the direction in which this new and unique business is headed and is continually adjusting and adopting new business practices in both technology and the policies & procedures required by banks and securities regulators.

Newnote Financial Contact Information

Paul Dickson
President, CEO & Director
Newnote Financial Corp.
CSE: NEU; OTCQB: NWWTF; FSE: 1W4
Suite 709-700 West Pender Street
Vancouver, BC V6C 1G8
Phone: 604-229-0480
Fax: 604-685-3833
web: www.newnote.com
Bitcoin exchange: www.cointrader.net
Online store builder: www.payivy.com
Payment processing: www.coinpayments.net

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of Newnote Financial Corp. The forward-looking information is based on certain key expectations and assumptions made by the company’s management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.